FDA advisory vote is boost for bluebird bio 13-Jun-2022 By Jane Byrne Two of bluebird bio’s gene therapy candidates get the nod from FDA advisors.
EU go-ahead for bluebird bio gene therapy for CALD 22-Jul-2021 By Jane Byrne Bluebird’s Lenti-D, or elivaldogene autotemcel, has won approval from the European Commission to treat children with a rare neurodegenerative disease called early cerebral adrenoleukodystrophy (CALD).
